IPO
-
-
-
-
-
-
-
Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights
-
-
-
-
-
-
-
Nuvectis Pharma (NVCT) Reports Positive Data for NXP900 in Triple Negative Breast Cancer Preclinical Models with an Integrin-Linked Kinase (ILK) Loss
-
-
-
-
-
-
-
Nuvectis Pharma, Inc. Announces Pricing of $16,000,000 Upsized Initial Public Offering of Common Stock
-
-
-
-
-
122,340 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

